Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Upsher-Smith Adds Absorica Alternatives

As Sawai’s US Division Partners With Australia’s Mayne On Isotretinoin Capsules

Executive Summary

Sawai’s Upsher-Smith unit has launched three further strengths of isotretinoin capsules in the US. The company has also partnered with Australia’s Mayne Pharma on US distribution for the rivals to Sun’s Absorica dermatology brand.

You may also be interested in...



FDA Approves Mayne’s Halobetasol Foam For Adolescents

Mayne Pharma has announced receiving US FDA approval for its Lexette (halobetasol propionate) 0.05% foam for the treatment of plaque psoriasis for use in adolescents. With Lexette, Mayne now markets more than twenty dermatology products in the US including four branded products. 

What’s Next? Five Things To Look Out For In June

In June, the $6bn Organon business, including a healthy biosimilars operation, will begin trading, while Coherus BioSciences aims to file for biosimilar Lucentis with partners Formycon and Bioeq.

Teva Launches First Generic Of Sun’s Absorica In US

Teva has launched the first US generic version of Absorica (isotretinoin), expanding its dermatological portfolio. The company has also launched generic erythromycin tablets in the US. Meanwhile, in its recent environmental, social and governance progress report, Teva has launched a plan to increase access to medicines globally by 2025.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151285

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel